Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

Trial Profile

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Dec 2018

At a glance

  • Drugs Everolimus (Primary) ; Lenvatinib (Primary)
  • Indications CNS cancer; Ewing's sarcoma; Glioma; Neuroectodermal tumours; Rhabdomyosarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 20 Aug 2018 Planned End Date changed from 30 Dec 2022 to 31 May 2022.
    • 20 Aug 2018 Planned primary completion date changed from 30 Jun 2022 to 31 May 2022.
    • 04 Jan 2018 Planned primary completion date changed from 31 Mar 2022 to 30 Jun 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top